Observational studyRheumatology international2021
Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort.
Observational study in Rheumatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Pan-disease blood protein profiles of rheumatic autoimmune diseases.Communications medicine · 2026Article
- Development of a HiFi-LAMP assay for the detection of herpes simplex virus type 1.Scientific reports · 2026Article
- A new, rapid, chemiluminescence enzyme assay for the detection of heparin-induced thrombocytopenia: a comparison between functional and immune heparin-induced thrombocytopenia assays.Research and practice in thrombosis and haemostasis · 2026Article
- Rheumatoid arthritis and cardiovascular disease in relation to cytomegalovirus infection: a pilot cross-sectional study.Frontiers in medicine · 2026Article
- Polyethylene glycol precipitation is a useful method for excluding the interference of unexplained elevated CA 19-9.Scientific reports · 2025Article
- Diode-based photoacoustic imaging for monitoring therapeutic response in rheumatoid arthritis.Biomedical optics express · 2025Article
- A Tool to Eliminate IgM Immunoassay Interference.The AAPS journal · 2025Article
- Anti-citrullinated protein antibody detection by hemagglutination.Rheumatology advances in practice · 2025Article
- Application of Monoclonal Anti-Mycolate Antibodies in Serological Diagnosis of Tuberculosis.Tropical medicine and infectious disease · 2024Article
- Endocrine and dog factors associated with semen quality.Scientific reports · 2024Article
- Multicenter comparison of analytical interferences of 25-OH vitamin D immunoassay and mass spectrometry methods by endogenous interferents and cross-reactivity with 3-epi-25-OH-vitamin DPractical laboratory medicine · 2024Article
- Intravenous Bacille Calmette-Guérin vaccination protects simian immunodeficiency virus-infected macaques from tuberculosis.Nature microbiology · 2023Article
- Rheumatoid Arthritis Has Won the Battle but Not the War: How Many Joints Will We Save Tomorrow?Medicina (Kaunas, Lithuania) · 2023Review
- Article
- COVID-19 infection and a repeated false positivity effect in HIV testing: A case report.IDCases · 2023Article
- ADAMTS13 Activity Measurement by ELISA and Fluorescence Resonance Energy Transfer Assay.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Review
- Unexpected Detection of Anti-SARS-CoV-2 Antibodies Before the Declaration of the COVID-19 Pandemic.Frontiers in medicine · 2022Article
- Heterophilic Interference of Rheumatoid Factor in TSH Immunometric Assay: A Cross-Sectional Observational Study.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to assess RF cross-reactivity to animal antibodies used in immunoassays, and to test if selected commercial immunoassays are vulnerable to interference from RF, causing false test results. Our study included samples from patients with RF-positive rheumatoid arthritis (RA) and controls (patients with RF-negative RA and psoriatic arthritis), included in an early arthritis-cohort. Reactivity to mouse IgG1, mouse IgG2a, rabbit IgG, bovine IgG, sheep/goat IgG and human IgG was analysed using in-house interference assays. RF-positive sera with strong reactivity to mouse IgG1 were analysed in three commercial immunoassays. To reveal interference, results before and after addition of blocking aggregated murine IgG1 were compared. Samples from 124 RF-positive RA patients and 66 controls were tested. We found considerably stronger reactivity toward animal antibodies, particularly mouse IgG1 (73% vs. 12%) and rabbit IgG (81% vs. 6%), in sera from RF-positive RA-patients compared to controls (p < 0.001). After selecting samples for testing in commercial assays, interference was revealed in 6/30 sera in the Architect β-hCG assay, 7/10 sera in the 27-plex cytokine assays, and in 2/33 samples in the Elecsys Soluble Transferrin Receptor assay. Our study revealed considerable RF reactivity to animal antibodies used in immunoassays and RF was associated with falsely elevated results in immunoassays used in clinical care and research. Clinicians, laboratorians, researchers and assay manufacturers must be alert to the risk of falsely elevated test results in RF-positive RA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.